Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

[1 ]Sendai Kousei Hospital, Sendai, Japan;

[2 ]Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan;

[3 ]Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan;

[4 ]Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan;

[5 ]Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan;

[6 ]Department of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan;

[7 ]Department of Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan;

[8 ]Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan;

[9 ]Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan;

[10 ]Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan;

[11 ]Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan;

[12 ]First Department of Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan;

[13 ]Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan;

[14 ]Department of Respiratory Medicine, Tohoku University, Sendai, Japan;